Carbapenemase Genes blaOXA23 and blaOXA58 Distribution among Acinetobacter baumanii Isolated from Clinical Isolates
DOI:
https://doi.org/10.46966/msjar.v6i2.273Keywords:
Carbapenems Resistance, MDR A. baumannii, blaOXA23 gene, blaOXA58 geneAbstract
Background: Acinetobacter baumannii is one of the most prevalent Gram-negative microbes associated with serious and fatal nosocomial infections. It is routine to use carbapenems as a treatment for A. baumannii infections. The dissemination of carbapenem resistance offers a major challenge to the treatment of life-threatening infections caused by these bacteria. Aim of Study: Determine which isolate of carbapenem-resistance A. baumannii have higher prevalence of the blaOXA23 and blaOXA58 gene at Al-Najaf city. Settings and Design: Cross-Sectional study. Methods and Materials: From December 2023 to July 2024, a total of 220 samples were collected in this cross-sectional study including urine (n=85,39%), wounds (n=55,25%) burns (n=45,20 %), sputum (n=20, 9%), blood (n=15, 7%) from patients at Al-Sadder Medical City, burn center unit, and private laboratories in Al-Najaf city. The identification and antibiotic susceptibility profile of A. baumannii were done by vitek2 compact system. The isolates were treated for PCR assays with specific primers for (blaOXA-23 gene, blaOXA-58 gene).Results: The recovery rate of A. baumannii isolates was (n= 16, 7.27%) from different clinical samples. Antibiotic-susceptibility patterns demonstrated that isolate of A. baumannii these isolates were multi-drug resistant (MDR). The MDR isolates were resistant to all 11 antibiotics classes tested in this study. The prevalence of blaOXA-23 gene (75%) was higher than blaOXA-58 gene (31.25%) in A.baumannii isolates Conclusion: Increased resistance to carbapenem antibiotic in Al-Najaf Hospitals serves to highlight how critical this issue is when treating multidrug-resistant A. baumannii infections that are life-threatening.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Eman J. Raheem, Ibtisam Habeeb Al-Azawi

This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.


















